Giulia Pasello

11PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsSolid tumoursCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Nov 09, 2025
Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors.

Francesca Lunardi, Alessandra Ferro, Luca Vedovelli

|Jan 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.

Ferdinandos Skoulidis, Bob T Li, Maximilian Hochmair

|Jul 02, 2024
Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.

Anna Tosi, Martina Lorenzi, Paola Del Bianco

|Mar 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Giulia Pasello, Martina Lorenzi, Daniela Scattolin

|Mar 05, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.

Giulia Pasello, Aline S C Fabricio, Paola Del Bianco

Pageof 2

Frequent Collaborators

4 joint publications

Laura Bonanno

4 joint publications

Valentina Guarneri

4 joint publications

PierFranco Conte

3 joint publications

Alessandra Ferro